Literature DB >> 24589438

The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential.

Himisha Beltran1.   

Abstract

N-myc (MYCN), a member of the Myc family of basic-helix-loop-helix-zipper (bHLHZ) transcription factors, is a central regulator of many vital cellular processes. As such, N-myc is well recognized for its classic oncogenic activity and association with human neuroblastoma. Amplification and overexpression of N-myc has been described in other tumor types, particularly those of neural origin and neuroendocrine tumors. This review outlines N-myc's contribution to normal development and oncogenic progression. In addition, it highlights relevant transcriptional targets and mechanisms of regulation. Finally, the clinical implications of N-Myc as a biomarker and potential as a target using novel therapeutic approaches are discussed. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24589438     DOI: 10.1158/1541-7786.MCR-13-0536

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  43 in total

1.  N-myc regulates growth and fiber cell differentiation in lens development.

Authors:  Gabriel R Cavalheiro; Gabriel E Matos-Rodrigues; Yilin Zhao; Anielle L Gomes; Deepti Anand; Danilo Predes; Silmara de Lima; Jose G Abreu; Deyou Zheng; Salil A Lachke; Ales Cvekl; Rodrigo A P Martins
Journal:  Dev Biol       Date:  2017-07-14       Impact factor: 3.582

2.  How to eliminate MYCN-positive hepatic cancer stem cells to prevent the recurrence?

Authors:  Go J Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

3.  Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Authors:  Wei Zhang; Bo Liu; Wenhui Wu; Likun Li; Bradley M Broom; Spyridon P Basourakos; Dimitrios Korentzelos; Yang Luan; Jianxiang Wang; Guang Yang; Sanghee Park; Abul Kalam Azad; Xuhong Cao; Jeri Kim; Paul G Corn; Christopher J Logothetis; Ana M Aparicio; Arul M Chinnaiyan; Nora Navone; Patricia Troncoso; Timothy C Thompson
Journal:  Clin Cancer Res       Date:  2017-11-14       Impact factor: 12.531

Review 4.  Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.

Authors:  John L Silberstein; Maritza N Taylor; Emmanuel S Antonarakis
Journal:  Curr Urol Rep       Date:  2016-04       Impact factor: 3.092

5.  Clear cell renal cell carcinoma: a comparative study of histological and chromosomal characteristics between primary tumors and their corresponding metastases.

Authors:  Julien Dagher; Solène-Florence Kammerer-Jacquet; Frédéric Dugay; Marion Beaumont; Alexandra Lespagnol; Laurence Cornevin; Grégory Verhoest; Karim Bensalah; Nathalie Rioux-Leclercq; Marc-Antoine Belaud-Rotureau
Journal:  Virchows Arch       Date:  2017-05-10       Impact factor: 4.064

6.  Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis.

Authors:  Marcela S Cavalcanti; Anne M Schultheis; Caleb Ho; Lu Wang; Deborah F DeLair; Britta Weigelt; Ginger Gardner; Stuart M Lichtman; Meera Hameed; Kay J Park
Journal:  Int J Gynecol Pathol       Date:  2017-01       Impact factor: 2.762

7.  MYCN Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid.

Authors:  Ruhina Maeshima; Dale Moulding; Andrew W Stoker; Stephen L Hart
Journal:  Nucleic Acid Ther       Date:  2020-04-02       Impact factor: 5.486

8.  A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.

Authors:  Huabo Wang; Anand Ramakrishnan; Steven Fletcher; Edward V Prochownik
Journal:  J Biol Methods       Date:  2015

9.  Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors.

Authors:  Johanna M Schafer; Brian D Lehmann; Paula I Gonzalez-Ericsson; Clayton B Marshall; J Scott Beeler; Lindsay N Redman; Hailing Jin; Violeta Sanchez; Matthew C Stubbs; Peggy Scherle; Kimberly N Johnson; Quanhu Sheng; Joseph T Roland; Joshua A Bauer; Yu Shyr; Bapsi Chakravarthy; Bret C Mobley; Scott W Hiebert; Justin M Balko; Melinda E Sanders; Phillip C C Liu; Jennifer A Pietenpol
Journal:  Sci Transl Med       Date:  2020-03-11       Impact factor: 17.956

10.  N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

Authors:  John K Lee; John W Phillips; Bryan A Smith; Jung Wook Park; Tanya Stoyanova; Erin F McCaffrey; Robert Baertsch; Artem Sokolov; Justin G Meyerowitz; Colleen Mathis; Donghui Cheng; Joshua M Stuart; Kevan M Shokat; W Clay Gustafson; Jiaoti Huang; Owen N Witte
Journal:  Cancer Cell       Date:  2016-03-31       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.